Lijun J. Wu

235 West University Street
Hohhot, 010021, China

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 116 publications

Bacterial Microenvironment-Responsive Nanopesticides for Sustainable Management of Tomato Bacterial Wilt.

Bacterial Microenvironment-Responsive Nanopesticides for Sustainable Management of Tomato Bacterial Wilt.

Journal: Langmuir : the ACS journal of surfaces and colloids

Published: July 08, 2026

Endoplasmic Reticulum-Mitochondria Calcium Drives Salivary Bioenergetics.

Endoplasmic Reticulum-Mitochondria Calcium Drives Salivary Bioenergetics.

Journal: Journal of dental research

Published: February 24, 2026

Efficacy of leflunomide in active Takayasu arteritis: a randomized double-blind placebo-controlled trial subtitle: Takayasu arteritis clinical trial in China (TACTIC).

Efficacy of leflunomide in active Takayasu arteritis: a randomized double-blind placebo-controlled trial subtitle: Takayasu arteritis clinical trial in China (TACTIC).

Journal: BMC medicine

Published: February 10, 2026

Research progress in diagnosis and treatment of non-tumorous salivary gland diseases

Research progress in diagnosis and treatment of non-tumorous salivary gland diseases

Journal: Beijing da xue xue bao. Yi xue ban = Journal of Peking University. Health sciences

Published: February 03, 2026

Smart Nanopesticide with Fungal Microenvironment-Responsive Release for Sustainable Management of Tomato Gray Mold.

Smart Nanopesticide with Fungal Microenvironment-Responsive Release for Sustainable Management of Tomato Gray Mold.

Journal: Langmuir : the ACS journal of surfaces and colloids

Published: February 02, 2026

Role of the SII and SIRI in risk prediction, disease activity assessment, and prog-nostic evaluation of Behçet disease uveitis

Role of the SII and SIRI in risk prediction, disease activity assessment, and prog-nostic evaluation of Behçet disease uveitis

Journal: Beijing da xue xue bao. Yi xue ban = Journal of Peking University. Health sciences

Published: December 16, 2025

Exploring clinical subtypes of Chinese patients with psoriatic arthritis based on cluster analysis: a national registry study (CREPAR V).

Exploring clinical subtypes of Chinese patients with psoriatic arthritis based on cluster analysis: a national registry study (CREPAR V).

Journal: Clinical rheumatology

Published: December 09, 2025

Efficacy, safety, and completion of modified short-course rifapentine and isoniazid for latent tuberculosis infection in patients with high-risk rheumatic disease: a multicentre, open-label, randomized, non-inferiority trial.

Efficacy, safety, and completion of modified short-course rifapentine and isoniazid for latent tuberculosis infection in patients with high-risk rheumatic disease: a multicentre, open-label, randomized, non-inferiority trial.

Journal: EClinicalMedicine

Published: November 09, 2025

Disparities in clinical characteristics and health-related quality of life among young, young-onset elderly and elderly-onset rheumatoid arthritis patients: A large-scale national survey.

Disparities in clinical characteristics and health-related quality of life among young, young-onset elderly and elderly-onset rheumatoid arthritis patients: A large-scale national survey.

Journal: Clinical rheumatology

Published: November 08, 2025

Efficacy and safety of mufemilast in patients with Behçet's syndrome: a phase 2 randomised clinical trial.

Efficacy and safety of mufemilast in patients with Behçet's syndrome: a phase 2 randomised clinical trial.

Journal: Annals of the rheumatic diseases

Published: October 20, 2025

Biopsychosocial determinants and gender disparities in health-related quality of life among rheumatoid arthritis patients: a nationwide multicentre study in China.

Biopsychosocial determinants and gender disparities in health-related quality of life among rheumatoid arthritis patients: a nationwide multicentre study in China.

Journal: Clinical and experimental rheumatology

Published: September 27, 2025

Efficacy and safety of secukinumab in patients with active psoriatic arthritis at Week 16 and up to 52 weeks: Results from a Phase III, randomized, double-blind, placebo-controlled bridging study in China.

Efficacy and safety of secukinumab in patients with active psoriatic arthritis at Week 16 and up to 52 weeks: Results from a Phase III, randomized, double-blind, placebo-controlled bridging study in China.

Journal: Chinese medical journal

Published: September 07, 2025

Showing 1-12 of 116

Last Updated: 09/26/2026